- Home
- NMRK vs NAMS Comparison
NMRK vs NAMS Comparison
Compare NMRK & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMRK
- NAMS
- Stock Information
- Founded
- NMRK 1929
- NAMS 2019
- Country
- NMRK United States
- NAMS Netherlands
- Employees
- NMRK N/A
- NAMS N/A
- Industry
- NMRK Real Estate
- NAMS Biotechnology: Pharmaceutical Preparations
- Sector
- NMRK Finance
- NAMS Health Care
- Exchange
- NMRK Nasdaq
- NAMS Nasdaq
- Market Cap
- NMRK 3.4B
- NAMS 3.1B
- IPO Year
- NMRK 2017
- NAMS N/A
- Fundamental
- Price
- NMRK $17.61
- NAMS $36.65
- Analyst Decision
- NMRK Strong Buy
- NAMS Strong Buy
- Analyst Count
- NMRK 5
- NAMS 10
- Target Price
- NMRK $19.00
- NAMS $43.70
- AVG Volume (30 Days)
- NMRK 1.2M
- NAMS 1.2M
- Earning Date
- NMRK 10-30-2025
- NAMS 11-06-2025
- Dividend Yield
- NMRK 0.68%
- NAMS N/A
- EPS Growth
- NMRK 94.50
- NAMS N/A
- EPS
- NMRK 0.59
- NAMS N/A
- Revenue
- NMRK $3,160,782,000.00
- NAMS $64,006,000.00
- Revenue This Year
- NMRK $19.70
- NAMS N/A
- Revenue Next Year
- NMRK $9.58
- NAMS N/A
- P/E Ratio
- NMRK $29.89
- NAMS N/A
- Revenue Growth
- NMRK 20.95
- NAMS 762.15
- 52 Week Low
- NMRK $9.65
- NAMS $14.06
- 52 Week High
- NMRK $19.84
- NAMS $41.47
- Technical
- Relative Strength Index (RSI)
- NMRK 39.73
- NAMS 57.00
- Support Level
- NMRK $17.31
- NAMS $36.30
- Resistance Level
- NMRK $19.84
- NAMS $39.03
- Average True Range (ATR)
- NMRK 0.62
- NAMS 2.13
- MACD
- NMRK -0.17
- NAMS -0.33
- Stochastic Oscillator
- NMRK 8.07
- NAMS 34.73
About NMRK Newmark Group Inc.
Newmark Group Inc is a commercial real estate advisory firm. It offers services, including leasing and corporate advisory services, investment sales, commercial mortgage brokerage, appraisal and valuation, project management, and property, among others. Newmark offers a diverse array of integrated services and products designed to meet the full needs of both real estate investors/owners and occupiers. The company provides real estate strategic consulting and systems integration services to CFI's clients including many Fortune and Forbes companies, owner-occupiers, government agencies, healthcare, and higher education clients.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.